Cremaffin Plus vs Cremaffin vs Duphalac for Constipation
Start with polyethylene glycol (PEG) as first-line therapy rather than any of these three options, but if choosing among them: use Cremaffin Plus (which contains sodium picosulfate) for more severe constipation requiring stimulant action, standard Cremaffin for mild cases, and avoid Duphalac (lactulose) as it is less effective and causes more side effects.
Evidence-Based Treatment Hierarchy
The 2023 AGA-ACG guideline provides clear direction 1:
- Strong recommendations (Grade A): Polyethylene glycol and sodium picosulfate
- Conditional recommendations (Grade B): Lactulose and magnesium oxide
This hierarchy directly informs the choice among your three options.
When to Use Each Formulation
Cremaffin Plus (Liquid Paraffin + Magnesium Hydroxide + Sodium Picosulfate)
Preferred for moderate-to-severe chronic constipation because:
- Contains sodium picosulfate, which has strong evidence (Grade A) supporting its efficacy 1
- The stimulant component provides more reliable bowel movements
- Combination therapy addresses multiple mechanisms: lubrication (liquid paraffin), osmotic effect (magnesium hydroxide), and stimulation (sodium picosulfate)
- Recent evidence confirms sodium picosulfate is well-tolerated with good efficacy 2
Cremaffin (Liquid Paraffin + Magnesium Hydroxide Only)
Use for mild constipation or maintenance therapy when:
- Patient needs gentler intervention without stimulant effects
- Magnesium oxide/hydroxide has conditional recommendation (Grade B) 1
- Less effective than options with stimulants but fewer side effects
- Appropriate when cost is a major concern
Duphalac (Lactulose)
Least preferred option among the three because:
- Only conditional recommendation (Grade B) in guidelines 1
- Directly inferior to PEG in head-to-head trials: worse stool frequency, consistency, and causes more vomiting and flatulence 3
- Less palatable than alternatives 4
- More abdominal discomfort and bloating 5, 2
- Should be reserved for when other options fail or are contraindicated
Clinical Algorithm
Step 1: Assess constipation severity
- Mild (infrequent symptoms, soft stools possible): Consider Cremaffin
- Moderate-to-severe (persistent symptoms, hard stools): Use Cremaffin Plus
- Refractory cases: Escalate to PEG-based laxatives
Step 2: Evaluate patient factors
- Palatability concerns: Avoid lactulose (Duphalac) - patients consistently rate it poorly 4
- Abdominal pain/bloating: Avoid lactulose - causes significantly more flatulence 3
- Need for predictable response: Choose Cremaffin Plus (sodium picosulfate provides reliable stimulation)
Step 3: Monitor response at 1-2 weeks
- If inadequate response on Cremaffin: Escalate to Cremaffin Plus
- If inadequate response on Cremaffin Plus: Switch to PEG (not lactulose)
Critical Caveats
Important limitations of the provided evidence: The "FDA" drug labels 6, 7 actually describe carbamazepine (an anticonvulsant), not the laxative formulations in question. This appears to be a data error. Therefore, specific dosing recommendations for these products cannot be extracted from the provided evidence.
Quality of life considerations:
- Lactulose causes significantly more gastrointestinal side effects that impair daily functioning 3
- Sodium picosulfate (in Cremaffin Plus) is better tolerated with fewer adverse effects than lactulose 2
- Liquid paraffin provides symptomatic relief through lubrication but lacks robust efficacy data
Cost-effectiveness: While not extensively studied in the evidence provided, magnesium-based laxatives (Cremaffin) are generally less expensive than combination products, which may influence choice when efficacy differences are modest 8.
The fundamental issue: None of these three options represent optimal first-line therapy. The strongest evidence supports PEG as the gold standard 1, 5, 3. If institutional or cost constraints limit you to these three choices, Cremaffin Plus offers the best evidence-based components, but recognize this is a compromise from guideline-recommended care.